Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Eli Lilly Vs Dr...

    Eli Lilly Vs Dr Reddys, Hospira: Court rules in favour of Lilly in Alimta alternate salt form patent lawsuit

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-13T09:15:48+05:30  |  Updated On 17 Aug 2021 12:02 PM IST

    The ruling came in the appeals of U.S. District Court decisions in the cases of Eli Lilly and Company v. Dr Reddy's Laboratories and Eli Lilly and Company v. Hospira, Inc. Previous rulings in Lilly's favour had precluded the generic companies from launching the alternative salt forms until the patent expires.


    INDIANAPOLIS: Eli Lilly and Company recently announced that the U.S. Court of Appeals for the Federal Circuit ruled in favour of Lilly, confirming that the Alimta (pemetrexed for injection) vitamin regimen patent would be infringed by competitors that had stated their intent to market alternative salt forms of pemetrexed prior to the patent's expiration in May 2022.


    The ruling came in the appeals of U.S. District Court decisions in the cases of Eli Lilly and Company v. Dr Reddy's Laboratories and Eli Lilly and Company v. Hospira, Inc. Previous rulings in Lilly's favour had precluded the generic companies from launching the alternative salt forms until the patent expires.


    If the patent is ultimately upheld through all remaining challenges, Alimta would maintain U.S. exclusivity until May 2022, preventing marketing of generic products for as long as the patent remains in force.


    "We're pleased with this decision," said Michael J. Harrington, Lilly's senior vice president and general counsel. "Lilly's extensive research to discover this patent deserves intellectual property protection, which has been confirmed in every challenge in the U.S. to date."


    On June 22, 2018, Lilly announced that the U.S. District Court for the Southern District of Indiana ruled in favour of Lilly that the Alimta vitamin regimen patent would be infringed by the use of Dr Reddy's alternative salt form of pemetrexed prior to the patent's expiration. The district court found the generic product would infringe under the doctrine of equivalents.


    In a separate decision on June 15, 2018, the District Court also ruled in favour of Lilly in the case of Eli Lilly and Company v. Hospira, Inc. denying Hospira's motion for summary judgment and granting Lilly's cross-motion for summary judgment.


    Both Dr Reddy's and Hospira had appealed the district court's decisions, leading to today's ruling.


    In March 2014, the U.S. Court for the Southern District of Indiana upheld the validity of the vitamin regimen patent. In August 2015, the same court ruled in Lilly's favour regarding infringement of the vitamin regimen patent. The U.S. Court of Appeals for the Federal Circuit confirmed these rulings in a unanimous decision in January 2017, finding the patent is valid and would be infringed by the generic challengers' proposed products.


    Separately, Lilly announced on April 2019 that the U.S. Court of Appeals for the Federal Circuit ruled in the company's favour regarding the patentability of the vitamin regimen for Alimta, upholding an October 2017 decision by the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office.


    Read Also: Eli Lilly gets USFDA nod for Cyramza to treat hepatocellular carcinoma

    AlimtaAlternate Salt FormAppeal BoardDr Reddy'sDr Reddy's LaboratoriesDr Reddy's LabsEli LillyFederal Circuitgeneric producthospiraInjectionMichael J HarringtonPatent LawsuitPatent TrialPemetrexedUS courtvitamin

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok